The latest Business updates from the science industry
by Heather Hobbs Unibloc Pump Acquired by May River Capital
Founded in 1984 by Harry Soderstrom, Unibloc Pump has built a strong reputation for innovation within critical sanitary process manufacturing applications, including the food and beverage, pharmaceutical, bakery and confection, meat and poultry, brewery, and transportation industries. Through the leadership of Harry Soderstrom, Unibloc Pump has witnessed signifi cant growth over the years at both its headquarters in the metro-Atlanta area as well as its second facility located in Beckum, Germany.
Harry Soderstrom Chris Stevens
Unibloc Pump, a 36-year leader in the manufacture of positive displacement pumps, strainers, valves, bubble traps and other solutions for sanitary fl ow control applications, has announced it has been acquired by May River Capital, a Midwest-based private equity fi rm focused on helping high-calibre industrial businesses grow and prosper.
“Unibloc Pump is launching a new and exciting chapter with May River Capital,” said Soderstrom. “May River’s approach to building business through collaboration is exactly what I was seeking as I looked ahead to the opportunities awaiting our company. We are pleased we’ve found a partner who values the engineering, skills, craftsmanship and most importantly, the culture we’ve nurtured here. This partnership will enable us to accelerate our growth initiatives and better serve our customers’ needs,” Soderstrom said.
Soderstrom will continue with Unibloc Pump as Chief Growth Offi cer, where he will utilise his expertise in driving growth for the company through fi nding new markets, customers, products, and business partners.
Joining the leadership team with Soderstrom will be Chris Stevens,
Chief Executive Offi cer, who will provide commercial leadership with strengths in business-to-business marketing, channel management, and sales.
“Harry’s years of industry expertise and leadership paired with Unibloc’s talented and hard-working employees have made the company the great success it is today,” Stevens said. “We are committed to building upon Harry’s rich legacy and investing in the resources to support the company’s continued growth,” added Stevens.
Unibloc Pump recently moved its US operations into a state-of-the- art facility located in Kennesaw, Georgia, which is three times larger than its prior facility located in Marietta, Georgia.
“We have more than tripled our plant footprint to dramatically increase capacity to better serve our customers and expand to new markets,” said Soderstrom. “The new facility will also help Unibloc Pump maintain its competitive edge in the industry by attracting top talent in the region,” he added.
More information online:
ilmt.co/PL/zp6L 54053pr@reply-direct.com
Pioneering Research Reveals Potential for Earlier Prostate Cancer Diagnostics
The University of Virginia in collaboration with Manchester UK based APIS Assay Technologies Ltd has discovered Hormone-Upregulated lncRNA within the lymphocyte-specifi c protein tyrosine kinase (HULLK) is detectable in non-invasive prostate cancer patient samples, providing a potential new approach for earlier diagnosis avoiding biopsy.
Dr Daniel Gioeli, Associate Professor, Microbiology, Immunology and Cancer Biology at the University of Virginia, has shown that HULLK could be isolated from urine of prostate cancer patients. He presented the data on the detection of HULLK in urine samples from patients with high grade prostate cancer (PCa) during the 2020 Annual Meeting of the Society for Basic Urologic Research, Inc (SBUR), held in November 2020.
HULLK, an unannotated lncRNA within exon six and the 3-UTR of the LCK gene, is dramatically upregulated by androgen in a dose- dependent manner and this hormone-induced increase is completely blocked by the anti-androgen enzalutamide. Remarkably, there was a signifi cant positive correlation between HULLK expression and high-grade PCa in three independent cohorts: the University of Virginia, the University of Texas Southwestern, and The Cancer Genome Atlas.
Dr Gioeli said: “Virtually all patients with metastatic prostate cancer (PCa) will relapse and develop lethal castration-resistant prostate cancer (CRPC). The new data being presented, continues to support the hypothesis on the potential use of HULLK as a biomarker for PCa.”
“The latest data, which demonstrates the presence of this biomarker in non-invasive biofl uids such as urine, is an exciting step forward,” stated Ian Kavanagh, COO, APIS Assays Technologies. “Our intention at APIS Assay Technologies is to implement HULLK into a clinically relevant signature for early detection of patients with metastatic prostate cancer and provide a guidance for further treatment.”
Company CEO Dr Schorr, added: “Overall lncRNAs are emerging as critical regulatory elements of many cellular biological processes, that’s why APIS is also working with other lncRNA biomarkers in additional cancer related indications.”
53999pr@reply-direct.com
UK MHRA announces Approval for Moderna COVID-19 Vaccine
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced approval (10th January) for Moderna’s RNA vaccine against COVID-19 for use under Regulation 174. The temporary authorisation permits the supply of COVID-19 Vaccine Moderna in Great Britain and is based upon the advice of the UK Commission on Human Medicines. “We appreciate the confi dence shown by the UK MHRA in COVID-19 Vaccine Moderna with this decision, which marks an important step forward in the global fi ght against COVID-19,” Stéphane Bancel said. “I want to thank the MHRA and the Commission on Human Medicines’ reviewers
for their tireless efforts. The authorisation of a product developed by Moderna is a signifi cant milestone on the Company’s 10-year journey and I would like to thank all our colleagues that have helped us get to this point.”
Following recommendation of the European Medicines Agency The European Commission also granted a conditional marketing authorisation (6th January 2021) for COVID-19 Vaccine Moderna. Deliveries of COVID-19 vaccine to EU and EEA Member States began on January 11. All shipments of the COVID-19 Vaccine Moderna are being conducted by Kuehne+Nagel, a world-leading logistics company
and will originate from its centralised pharma hub in Europe.
The UK is the fi fth jurisdiction to authorise COVID-19 Vaccine Moderna, following the United States on 18th December 2020, Canada on 23rd December 2020, Israel on 4th January 2021 and the European Union on 6th January 2021. Additional authorisations are currently under review in a number of countries including Singapore and Switzerland.
54056pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
